## Staphylococcus aureus: Antibiotic Susceptibility & Resistance Mechanisms **Key Point:** Vancomycin resistance in S. aureus is extremely rare and not a routine clinical concern. Vancomycin remains the gold standard for MRSA infections, including toxic shock syndrome and severe infections. ### Antibiotic Resistance Profile of S. aureus | Resistance Type | Mechanism | Clinical Relevance | |---|---|---| | **Methicillin-Resistance (MRSA)** | mecA gene encodes PBP2a with low affinity for β-lactams | Common; requires vancomycin or alternatives | | **Vancomycin Susceptibility** | S. aureus remains universally susceptible | Gold standard for MRSA; MIC typically ≤1 μg/mL | | **Linezolid Susceptibility** | Used for serious infections; resistance rare | Reserved for severe/refractory cases | | **Doxycycline/Tetracycline** | Often effective for community-acquired MRSA | Oral option for less severe infections | **High-Yield:** Vancomycin-resistant S. aureus (VRSA) is exceptionally rare worldwide (< 10 documented cases). It is NOT a widespread clinical problem and is not the standard resistance pattern. **Clinical Pearl:** In the clinical case presented (mastitis with β-hemolytic, coagulase-positive S. aureus), vancomycin would be appropriate empiric therapy if MRSA is suspected. Linezolid is reserved for special circumstances (CNS penetration, intolerance to vancomycin). **Mnemonic: MRSA Resistance — mecA gene** — Methicillin-Resistant S. aureus uses the mecA gene to encode PBP2a, which has low affinity for β-lactams. ### Why This Patient Likely Has MRSA - Community-acquired infection (Delhi) - Rapid progression with systemic toxicity - MRSA prevalence in India is high in healthcare and community settings - Vancomycin or linezolid would be appropriate; but vancomycin is first-line
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.